Front Matter (PDF) - Investigative Ophthalmology & Visual Science

McCarey et al.
Polack and Sugar
Albert et al.
Kreuger et al
Binder et al.
Green et al.
Jampol etal.
Katz et al.
Malik et al.
Levy
Wickham and Worthen
van Alphen
Chen and Chylack
Kurzel and Heinrikson
JUNE 1976 Vol. 15/6
A journal of Clinical and Basic Research
Official Publication of the Association for
Research in Vision and Ophthalmology
Phacoemulsification, 449
Phacoemulsification, 458
Herpes hominis keratitis therapy, 470
Lacrimal gland sialic acid, 479
Oxytocic antibodies, 481
Stromal sodium binding, 484
Nitrogen mustard, 486
Timolol ophthalmic solution, 489
Isoproterenol and norepinephrine, 492
Axoplasmic transport, 495
Pericanalicular region, 499
Intraocular adrenergic receptors, 502
Lens phosphofructokinase, 505
Ocular bilirubin, 509
The C.V. Mosby Company
INOPAO 15 (6) 443-512 (1976) A

Severe ocular inflammation
calls for potent therapy...
The basis for a rational choice between
FML® (fluorometholone) and Pred Forte® (prednisolone acetate) 1%
When to use a potent steroid. If not treated
promptly and effectively, ocular inflammation is
at best painful and unsightly. At worst, it's
potentially damaging to the patient's vision. The
more severe the inflammatory condition, the
greater the need for therapeutic potency. For
example, FML and Pred Forte provide the high
level of anti-inflammatory activity needed to
effectively treat even the most severe steroid
responsive inflammation of the palpebral and
bulbar conjunctiva, cornea and anterior segment
of the globe.
The basic rationale behind the use of potent
ophthalmic steroids such as FML and Pred
Forte is to maintain functional integrity of the
eye. In general, as long as evidence of active
inflammation persists, it may be hazardous to
discontinue steroid therapy. Use of potent
steroids may in fact help preserve the ocular
structure. 1
When not to use potent steroids. Despite
their usefulness, there are times when potent
steroids (and mild ones too, for that matter)
should be used with extreme caution-or not at
all. It is generally agreed that untreated purulent
infections, most viral diseases and ocular
fungal infestations should be considered as
contraindications to the use of these agents.
Indications and methods of use. Either FML
or Pred Forte may be used to treat moderately
severe to severe steroid responsive inflammatory
conditions such as iritis, uveitis, iridocyclitis,
episcleritis and resistant ocular allergy. In addition,
data 2 made available recently attest to the
usefulness of FML in long-term treatment of
inflammation following cataract removal and
keratoplasty. The patient photos to the right
demonstrate the effectiveness of both FML and
Pred Forte in severe ocular inflammation.
The usual method of administering either FML
or Pred Forte is to instill one or two drops into
the conjunctival sac two to four times a day.
But to provide maximum therapeutic effectiveness
when the severity of the inflammation dictates,
the dosage can be safely increased to two
drops every hour during the first 24 to 48 hours.
Seminais
l~ IVIL_ (fluorometholone) 0.1% Liquifilm® Sterile Ophthalmic Suspension
ACTIONS Inhibition of the inflammatory response to inciting
agents of mechanical, chemical or immunological nature. No
generally accepted explanation of this steroid property has
been advanced. Adrenocorticosteroids and their derivatives
are capable of producing a rise in intraocular pressure. In
clinical studies on patients' eyes treated with both dexamethasone
and fluorometholone, fluorometholone demonstrated
a lower propensity to increase intraocular pressure than did
dexamethasone. INDICATIONS For steroid responsive inflammation
of the palpebral and bulbar conjunctiva, cornea and
anterior segment of the globe. CONTRAINDICATIONS Acute
superficial herpes simplex keratitis. Fungal diseases of ocular
structures. Vaccinia, varicella and most other viral diseases of
the cornea and conjunctiva. Tuberculosis of the eye. Hypersensitivity
to the constituents of this medication. WARNINGS
Steroid medication in the treatment of herpes simplex keratitis
(involving the stroma) requires great caution; frequent slitlamp
microscopy is mandatory. Prolonged use may result in
glaucoma, damage to the optic nerve, defects in visual acuity
and fields of vision, posterior subcapsuiar cataract formation,
or may aid in the establishment of secondary ocular infections
from fungi or viruses liberated from ocular tissue. In those
diseases causing thinning of the cornea or solera, perforation
has been known to occur with use of topical steroids. Acute
purulent untreated infection of the eye may be masked or
activity enhanced by presence of steroid medication. Safety
and effectiveness have not been demonstrated in children of
the age group 2 years or below. Use In Pregnancy: Safety of
the use of topical steroids during pregnancy has not been
established. PRECAUTIONS As fungal infections of the cornea
are particularly prone to develop coincidentally with long-term
local steroid applications, fungus invasion must be suspected
in any persistent corneal ulceration where a steroid has been
used or is in use. Intraocular pressure should be checked
frequently. ADVERSE REACTIONS Glaucoma with optic nerve
damage, visual acuity or field defects, posterior subcapsular
cataract formation, secondary ocular infection from pathogens
liberated from ocular tissues, perforation of the globe. DOSAGE
AND ADMINISTRATION 1 to 2 drops instilled into the conjunctival
sac two to four times daily. During the initial 24 to 48 hours
the dosage may be safely increased to 2 drops every hour.
Care should be taken not to discontinue therapy prematurely.

FME
PredFbrte
(fluorometholone) (prednisolone acetate) 1%
FML vs Pred Forte: A choice. Both FML and Pred Forte work. FML has been shown to have
less propensity than dexamethasone to raise IOR And recent animal data 3 indicate that Pred Forte
exhibits maximal corneal penetration, through intact epithelium, compared to commonly used
steroid phosphate and alcohol derivatives. So when potent anti-inflammatory activity is required
and your clinical judgement anticipates something beyond short-term therapy, FML appears to be
the drug of choice. But for severe disorders where safety is less of a concern, Pred Forte
provides a potent alternative to FML.
Potency you can see
y
Patient CH. White male. Age 46. Acute episcleritis secondary
to rheumatoid arthritis. Treatment started 2/24: FML one
drop every hour for 48 hours then one drop every two hours
for 36 hours then one drop every four hours thereafter
r
Patient CH on 3/9. FML therapy stopped.
References
1. Leopold, I.H. The steroid shield in ophthalmology, Trans
Amer Acad Ophth & Oto 71:273-289, 1967,
2. Castroviejo, R. Data presented at 79th American
Academy of Ophthalmology and Ototaryngology, Dallas,
Oct. 1974.
Patient LV. White male. Age 57. Acute episcleritis. Treatment
started 2/27: Pred Forte one drop every hour for 48 hours
then one drop every two hours for 36 hours then one drop
every four hours thereafter; warm compresses and
scopolamine ointment twice daily.
Patient LV on 3/12. Pred Forte therapy stopped.
3. Leibowitz, Howard M., Data presented at 79th American
Academy of Ophthalmology and Ototaryngology, Dallas,
Oct. 1974.
Photos by Dr. Ira Abrahamson, Cincinnati, Ohio
Pred Forte' (prednisolone acetate) 1% Sterile Ophthalmic Suspension
INDICATIONS For steroid responsive inflammation of the
palpebral and bulbar conjunctiva, cornea and anterior segment
of the globe. CONTRAINDICATIONS Acute untreated purulent
ocular infections, acute superficial herpes simplex (dendritic
keratitis), vaccinia, varicella and most other viral diseases of
the cornea and conjunctiva, ocular tuberculosis, and fungal
diseases of the eye, and sensitivity to any components of the
formulation. WARNINGS 1. In those diseases causing thinning
of the cornea, perforation has been reported with the use of
topical steroids. 2. Since PRED FORTE® contains no antimicrobial,
if infection is present appropriate measures must be taken
to counteract the organisms involved. 3. Acute purulent infections
of the eye may be masked or enhanced by the use of
topical steroids. 4. Use of steroid medication in the presence
of stromal herpes simplex requires caution and should be
followed by frequent mandatory slit-lamp microscopy. 5. As
fungal infections of the cornea have been reported coincidentally
with long-term local steroid applications, fungal invasion
may be suspected in any persistent corneal ulceration
where a steroid has been used, or is in use. 6. Use of topical
corticosteroids may cause increased intraocular pressure in
certain individuals.This may result in damage to the optic nerve
with defects in the visual fields. It is advisable that the intraocular
pressure be checked frequently. 7. Use in Pregnancy-
Safety of intensive or protracted use of topical steroids during
pregnancy has not been substantiated. PRECAUTIONS Posterior
subcapsular cataract formation has been reported after
heavy or protracted use of topical ophthalmic corticosteroids.
Patients with histories of herpes simplex keratitis should be
treated with caution. ADVERSE REACTIONS Increased intraocular
pressure, with optic nerve damage, defects in the visual
fields. Also posterior subcapsular cataract formation, secondary
ocular infections from fungi or viruses liberated from
ocular tissues, and perforation of the globe when used in conditions
where there is thinning of the cornea o r sclera. Systemic
side effects may occur with extensive use of steroids. DOSAGE
AND ADMINISTRATION 1 to 2 drops instilled into the conjunctival
sac two to four times daily. During the initial 24 to 48 hours
the dosage may be safely increased to 2 drops every hour.
Care should be taken not to discontinue therapy prematurely.
Irvine Califaria/PohteClaire,P.Q.,Canada

Novascan: the User's SEM
Zeiss introduces Novascan, an SEM with 100A edge resolution
guaranteed, magnification from 5X to 150.000X,
and accelerating voltages of 1-5, 15, and 30kV. Like all
Zeiss electron microscopes, its design reflects first and
foremost the needs of the user:
The most accessible
chamber
Novascan is the only SEM with true access to the chamber
from above. It opens automatically at the touch of a
button, accepts the largest of samples, lets you optimize the
positions of specimen and detectors with ease. Since it has
more ports than any other SEM, you can permanently attach
additional detectors or accessories, e.g. an X-ray analyzer of
your choice. And the large 5-axis goniometer stage is permanently
mounted for utmost stability.
The finest TV image
You won't believe the quality of the TV image until you
see it. Use it at high magnifications for critical focusing, at
low magnifications for specimen orientation. Then switch for
recording to the high-resolution CRT that's combined with the
built-in push-button controlled camera.
The most attractive price
For under $40,000, you get features you'd never expect.
Besides the secondary electron mode, standard are also the
back-scattered and cathodoluminescence electron modes—as
are signal inversion, reduced raster, 90° scan rotation, X-Y
±20 micron scan shift, and gamma contrast enhancement.
There is also a full line of accessories for special applications.
For complete details, write or call today.
Nationwide service
Carl Zeiss, Inc., 444 5th Avenue, N.Y., N.Y. 10018 (212) 730-4400. Branches in: Atlanta, Boston, Chicago, Columbus, Houston,
Los Angeles. San Francisco. Washington. D.C. In Canada: 45 Vallevbrook Drive. Don Mills. Ont.. M3B 2S6. Or call (416) 449-4660.

Page 4
[ Ophttialmid
Ointment \
SODIUM i
CHLORIDE!
5% I
iflill
Muro
Ointment
Sodium Chloride
MURO OINTMENT NO. 128 / SUPPLIED 1/8 02.
An ointment of hypertonic sodium chloride solution in a
base of lanolin, liquid petrolatum and white petrolatum.
Apply to conjuctiva at bedtime.
TO REDUCE CORNEAL EDEMA
Murocoll Methylcellulose
4000 cps 0.9%
with Sodium Chloride 5%
MUROCOLL PRODUCT NO. 4 / SUPPLIED 15cc and 30cc
A hypertonic solution of sodium chloride with methylcellulose.
Preservatives - methylparaben and propylparaben.
TO REDUCE CORNEAL EDEMA: 1 or 2 drops in affected
eye 3 times a day or as directed by the physician.
MURO preparations are available to all pharmacies and
hospitals through their drug wholesaler.
Complete ophthalmologic formulary available on request.
Federal law prohibits dispensing without prescription.
MURO PHARMACAL LABORATORIES, INC.
121 Liberty Street • Quincy, Mass. 02169
Area Code 617 • 479 2680

The new
generation of
disposable
cryoextractors
Reliability is the keynote of the all new 2001.
Eight proven design changes project the
2001 into a totally new product generation.
The 2OOFs unique 10 second delayed
response feature allows you to go on warm for
maximal adherence and ice ball formation. It is
the only simple disposable with this singular
advantage of warm or cold contact. With a running
time in excess of two minutes you have
ample margin time to compensate for any minor
interruptions.
The 2001 has the advantage of being a
fine surgical instrument rather than just a gas •!
container with a spout or delivery tube.
Of CONNECTICUT INCORPORATED
77O RIVER ROAD. SHELTON. CT O6484 2O3/?29-6321

Topcon Advances Projection Perimetry
Another Important Step.
The SBP-11 is recognized for its
accuracy and ease of operation in
critical perimetry field testing because
of our constant monitoring for improvements
made possible through new
technological developments.
One such improved feature on the
SBP-11 is a new device for occluding
the target. Its smoothness and silence
enables the operator to achieve optimum
accuracy of measurements.
TOPCON SBP-11
1
Other significant advantages of the
SBP-11 include:
• Reproducible environmental conditions
for accuracy in subsequent
examinations.
• Constant monitoring of patient's
fixation with sighting telescope.
• Automatic recording probe with manual
override (standard equipment.)
These features combined with a reasonable price and IMMEDIATE
AVAILABILITY should make the Topcon SBP-11 your first choice for keeping
in step with today's sophisticated diagnostic techniques. Contact your
Topcon distributor or write us for details.
TOPCON
A New V\forld of Precision Optics
Topcon Instrument Corp. of America, 9 Keystone Place, Paramus, New Jersey 07652

For uninterrupted control of I.O.R
...never more than one or two instillations
Page 10
Scanning electron microscopy of
primate trobecular meshwork (XOOO):
Viewed here is Schlemm's canal
along with uveal and corneoscleral
meshwork. (Photo courtesy
Douglas R. Anderson, M.D.]
This area is the site of the prime
pathologic changes which are
responsible for glaucoma and the
focus of most of the medical
procedures for treatment of the disease.

Because PHOSPHOLINE IODIDE is long-acting, it can help provide
uninterrupted control of intraocular pressure in chronic simple [open-angle)
glaucoma or glaucoma secondary to aphakia. Just one or, at most,
two instillations of PHOSPHOLINE IODIDE (one at bedtime, and, if necessary,
one in the morning) are generally needed.
Although PHOSPHOLINE IODIDE is longer-acting than other miotics,
it is not more potent. With four concentrations available, it offers a high degree of
dosage flexibility for uninterrupted control of intraocular pressure... used alone
or in combination with other medication.
When starting PHOSPHOLINE IODIDE therapy 0.03%-the lowest strength -
is the logical choice. If strengths of 0.06%, 0.125%, or 0.25% are required,
the initial use of the 0.03% will be helpful in smoothing the transition.
PHOSPHOLINE IODIDE' BE5K3&
(echothiophate iodide for ophthalmic solution)
See next page of advertisement lor prescribing information
Page 11

PHOSPHOLINE IODIDE
®
(echothiophate iodide)
in the management of
chronic simple (open-angle)
glaucoma or glaucoma
secondary to aphakia
BRIEF SUMMARY
(For full prescribing information, see package circular]
PHOSPHOLINE IODIDE"
(ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION)
PHOSPHOLINE IODIDE is a long-acting cholinesterase inhibitor
for topical use.
Indications: Glaucoma-Chronic open-angle glaucoma. Subacute
or chronic angle-closure glaucoma after iridectomy or
where surgery is refused or contraindicated. Certain non-uveitic
secondary types of glaucoma, especially glaucoma following
cataract surgery.
Accommodative esotropia-Concomitant esotropias with a
significant accommodative component.
Contraindications: 1. Active uveal inflammation.
2. Most cases of angle-closure glaucoma, due to the possibility
of increasing angle block.
3. Hypersensitiyity to the active or inactive ingredients.
Warnings: 1. Use in Pregnancy: Safe use of anticholinesterase
medications during pregnancy has not been established, nor
has the absence of adverse effects on the fetus or on the
respiration of the neonate.
2. Succinylcholine should be administered only with great
caution, if at all, prior to or during general anesthesia to patients
receiving anticholinesterase medication because of possible
respiratory or cardiovascular collapse.
3. Caution should be observed in treating glaucoma with
PHOSPHOLINE IODIDE in patients who are at the same time
undergoing treatment with systemic anticholinesterase medications
for myasthenia gravis, because of possible adverse
additive effects.
Precautions: 1. Gonioscopy is recommended prior to initiation
of therapy.-
2. Where there is a quiescent uveitis or a history of this condition,
anticholinesterase therapy should be avoided or used
cautiously because of the intense and persistent miosis and
ciliary muscle contraction that may occur.
3. While systemic effects are infrequent, proper use of the
drug requires digital compression of the nasolacrimal ducts for
a minute or two following instillation to minimize drainage into
the nasal chamber with its extensive absorption area. The hands
should be washed immediately following instillation.
4. Temporary discontinuance of medication is necessary if
salivation, urinary incontinence, diarrhea, profuse sweating,
muscle weakness, respiratory difficulties, or cardiac irregularities
occur.
5. Patients receiving PHOSPHOLINE IODIDE who are exposed
to carbamate or organophosphate type insecticides and
pesticides (professional gardeners, farmers, workers in plants
manufacturing or formulating such products, etc.) should be
Page 12
warned of the additive systemic effects possible from absorption
of the pesticide through the respiratory tract or skin. During
periods of exposure to such pesticides, the wearing of respiratory
masks, and frequent washing and clothing changes
may be advisable.
6. Antichqlinesterase drugs should be used with extreme caution,
if at all, in patients with marked vagotonia, bronchial
asthma, spastic gastrointestinal disturbances, peptic ulcer, pronounced
bradycardia and hypotension, recent myocardial infarction,
epilepsy, parkinsonism, and other disorders that may
respond adversely to vagotonic effects.
7. Anticholinesterase drugs should be employed prior to
ophthalmic surgery only as a considered risk because of the
possible occurrence of hyphema.
8. PHOSPHOLINE IODIDE (echothiophate iodide) should be
used with great caution, if at all, where there is a prior history of
retinal detachment.
Adverse Reactions: 1. Although the relationship, if any, of retinal
detachment to the administration of PHOSPHOLINE IODIDE
has not been established, retinal detachment has been reported
in a few cases during the use of PHOSPHOLINE IODIDE in
adult patients without a previous history of this disorder.
2. Stinging, burning, lacrimation, lid muscle twitching, conjunctival
and ciliary redness, browache, induced myopia with
visual blurring may occur.
3. Activation of latent iritis or uveitis may occur.
4. Iris cysts may form, and if treatment is continued, may
enlarge and obscure vision. This occurrence is more frequent
in children. The cysts usually shrink upon discontinuance of
the medication, reduction in strength of the drops or frequency
of instillation. Rarely, they may rupture or break free into the
aqueous. Regular examinations are advisable when the drug is
being prescribed for the treatment of accommodative esotropia.
5. Prolonged use may cause conjunctival thickening, obstruction
of nasolacrimal canals.
6. Lens opacities occurring in patients under anticholinesterase
therapy have been reported; routine examinations should
accompany prolonged use.
7. Paradoxical increase in intraocular pressure may follow
anticholinesterase instillation. This may be alleviated by prescribing
a sympathomimetic mydriatic such as phenylephrine.
Overdosage: Antidotes are atropine, 2 mg parenterally;
PROTOPAM" CHLORIDE (pralidoxime chloride), 25 mg per kg
intravenously; artificial respiration should be given if necessary.
How Supplied: Four potencies are available. 1.5 mg package
for dispensing 0.03% solution; 3.0 mg package for 0.06% solution;
6.25 mg package for 0.125% solution; 12.5 mg package
for 0.25% solution. Also contains potassium acetate (sodium
hydroxide or acetic acid may have been incorporated to adjust
pH during manufacturing), chlorobutanol (chloral derivative),
mannitol, boric acid and exsiccated sodium phosphate.
7630
The Ophthalmos Division
AYERST LABORATORIES
New York, N.Y. 10017

investigative ophthalmology
A Journal of Clinical and Basic Research
Official Publication of the Association for Research in Vision and Ophthalmology
EDITOR
Herbert E. Kaufman, M.D.
Professor of Ophthalmology and Pharmacology
College of Medicine, University of Florida
Gainesville, Florida 32610
Manuscripts
Address correspondence related to manuscripts
to the Editor, Herbert E. Kaufman, M.D., Department
of Ophthalmology, College of Medicine,
University of Florida, Gainesville, Florida 32601.
Scope and selection. Investigative Ophthalmology
is intended to convey information to those interested
in all areas of vision research. We welcome
the submission of manuscripts describing
laboratory and clinical investigations of the eye
and the visual processes. Papers submitted for
publication should be original and should not be
submitted for publication elsewhere. Papers submitted
by non-members of the Association for
Research in Vision and Ophthalmology will be
given equal consideration. Papers should be
written in English and contributed solely to
Investigative Ophthalmology. Preference will be
given to timely reports, to manuscripts of 2,000
words or less (approximately eight double-spaced
typewritten pages), and to reports of broadest
general interest.
Statements and opinions expressed in the articles
and communications herein are those of the
author(s) and not necessarily those of the Editors)
or publisher and the Editor(s) and publisher
disclaim any responsibility or liability for
such material. Neither the Editor(s) nor the
publisher guarantee, warrant, or endorse any
product or service advertised in this publication,
nor do they guarantee any claim made by the
manufacturer of such product or service.
Style and organization. Articles should be written
so as to be easily understandable to vision researchers
in many fields. Abstracts should be as
free of jargon and specialized language as possible
and should specifically state the conclusions of the
study. All investigators should specify any direct
or indirect financial interest involved in the outcome
of any paper or study, and all sources of
support.
Submit the original and three (3) copies of
the manuscript and illustrations. Type manuscript
double-spaced on one side of the paper. The
following organization is recommended: 1. Abstract
(250 words or less orienting the problem,
describing the major observations, and stating the
principal conclusion). 2. Introduction and objective
of study (omit extensive reviews of the
literature). 3. Methods and experimental design
(brief but compatible with repetition of the work;
refer to published procedures by reference only).
Editorial communications
PUBLISHER
The C. V. Mosby Company
11830 Westline Industrial Drive
St. Louis, Missouri 63141, U. S. A.
4. Results (describe with minimum of discussion
—use such tables, photographs, and charts as
are necessary to clarify and document the text).
5. Discussion (limit to the data presented, their
significance, and their limitations; avoid unsupported
hypotheses). Avoid unusual abbreviations;
employ standard chemical or nonproprietary pharmaceutical
nomenclature. (See Style Manual for
Biological Journals, 1960, American Institute of
Biological Sciences, 2000 P Street, N.W., Washington,
D. C. 20036.)
Key words. A list of 5 to 10 key words should
be provided on a separate sheet. A selection will
be made from these and printed at the head
of the article to facilitate indexing and retrieval
for the medical literature.
References. Restrict the bibliography to pertinent
references. Refer to them in the text by number
only, and list and number them at the end of
the manuscript in the order of their mention,
using style found in the Cumulated Index, Medicus
and in the following order: 1. Journal references:
authors, title, journal, volume, page, and
year. 2. Book references: authors, title, edition,
city, year, and publisher. It is the author's responsibility
to verify each reference.
Illustrations. Results may be presented in tables
or figures, but only under exceptional circumstances
should the same data be presented in
both. Illustrations should be numbered consecutively
in Arabic, and marked lightly on the
back with figure number, author's name, and
"top." Type legends on a separate sheet. Provide
unmounted, glossy photographic prints in which
the details are clearly evident, or original illustrations
on good quality paper on which the lining
and lettering are done with India ink. Approximately
three full pages of halftone illustrations,
or their equivalent, are permitted without extra
charge. Illustrations in excess of this amount will
be billed to the author at approximately $25.00
per full page. Authors who wish their electron
micrographs to be printed on special paper will
be billed at $52.00 per page. Arrangements should
be made with the Editor for the use of color
plates.
Reports. Special consideration for rapid review and
prompt publication will be given to Reports. These
should be written in the same format as regular
papers, including an abstract, but should be no
longer than 5 double-spaced, typewritten pages
in length, and may include up to 4 figures or
tables.
June 1976 Page 13

FIRST
PREFILLED
DISPOSABI
^SYRINGE FO
FLUORESC
ANGIO
Fluorescite' Irije 1
(Fluorescein Sodium Injec
(Syringe contains 5 ml of Fluorescite® Injection 10% With
a 10 rnl capacity to facilitate aspiration) ^
Modern angiography and
ophthalmoscopy techniques
are now made more
convenient with ALCON's
new prefilled, ready-to-use
Fluorescite® Syringe.
Completely disposable, it
prevents spillage, assures
fluorescein sterility and
eliminates the possibility
of foreign matter
contamination.
From ...of course.
Alcon Laboratories, Inc., Fort Worth, Texas 76101
10%
\
FLUORESCITE" INJECTION
(Fluorescein Sodium Injection)
Sterile Aqueous Solution
DESCRIPTION: Syringe: A sterile
aqueous solution of Fluorescein
Sodium (equivalent to Fluorescein
10%)withSodium Hydroxide and/or
Hydrochloric Acid (to adjust pH),
and Water for Injection. Ampul:
A sterile aqueous solution of
Fluorescein Sodium (equivalent lo
Fluorescein 5% or 10%) with Sodium
Bicarbonate (2.03% in 5%, 4.06%
in 10%), Sodium Hydroxide (to
adjust pH). Water for Injection.
CONTRAINDICATIONS: Hypersensitivity
to any component. PRE-
CAUTIONS: Use with caution in
patients with a history of hypersensitivity,
allergies, asthma, etc.
ADVERSE REACTIONS: Nausea,
headache, gastrointestinal distress,
urticaria and other symptoms of
hypersensitivity, cardiac arrest,
basilar artery ischemia, thrombophlebitis
at injected site, and severe
shock have occurred. DOSAGE:
Inject contents of syringe or ampul
rapidly into antecubital vein. An
antihistamine and an ampul of 0.1%
epinephrine for intravenous or intramuscular
emergency use should
always be available. HOW SUP-
PLIED: 10% in 10 ml disposable
syringe (5 ml fill) and 5 ml ampul.
5% in 10 ml ampul.